Biometrics company has £150,000 funding at its fingertips
DISRUPTIVE fingerprint technology company Touch Biometrix has secured a funding boost to eradicate the need for computer and mobile phone passwords.
The initial £150,000 seed investment from Deepbridge Capital will enable the St Asaph firm to develop new fingerprint sensors for a range of consumer electronics, providing enhanced security for users.
Touch Biometrix was founded in 2017 by Dr Mike Cowin with the aim of becoming one of the world’s top five fingerprint sensor suppliers by 2023. Dr Cowin is regarded as one of the industry’s leading experts.
Based on proprietary technology and sensing algorithms, the company is developing a range of fingerprint sensors of any shape or size for a more convenient user experience on a wider range of products, including smartphones and laptops.
Chief executive Dr Cowin said: “Our new manufacturing model is set to disrupt the market in terms of performance and cost, at less than $1 a unit. Fast, secure and impossible to spoof, our technology will eliminate the need for passwords.
“We will be using the money from the initial seed-funding round to establish a minimum viable product in collaboration with our supply chain partners.
“The demand for user authentication and mobile payment services is driving tremendous growth. The industry predicts that biometrics will be standard in 90% of mobile devices in the next four years, generating 1.37 trillion mobile device transactions.”
Ian Warwick, managing partner at Chester-based Deepbridge Capital, said: “We are delighted to be working in partnership with Touch Biometrix at what is an exciting time for the biometric industry.
“We understand there is an increasing need for secure user authentication technology and we believe Touch Biometrix has the capability to move quickly in this market.”
The market demand for fingerprint sensors is expected to exceed 1.5 billion units per year by 2020, with the global market for biometrics predicted to reach $15bn by 2025.
Deepbridge Capital provides funding to a portfolio of growth-focused technology and life sciences companies across the UK.